“After positive feedback from FDA during our recent Type D meeting, we are excited to initiate start-up activities for the phase 1 clinical trial and are delighted to have found an excellent partner in SAPRO,” said Michael Baker, Chief Executive Officer and Managing Director of Arovella. …
Arovella advances ALA-101 program with CRO appointment and Phase 1 trial preparations
October 29, 2025 Australian Biotech
Latest Video
New Stories
-
OncoSil charts a new growth phase as Chairman outlines progress and opportunities
November 19, 2025 - - Latest News -
CSL unveils US expansion, cementing its position as a global biopharma leader
November 19, 2025 - - Latest News -
Cleo Diagnostics appoints U.S. oncologist as first key opinion leader
November 19, 2025 - - Australian Biotech -
IDT Australia resets strategy as advanced therapies drive new phase of growth
November 19, 2025 - - BioPharma -
Dimerix Phase 3 kidney trial clears seventh safety review
November 19, 2025 - - Australian Biotech -
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech